LLY
Eli Lilly and Company
LLY has the edge over RGNX overall, supported by stronger fundamentals and lower modeled downside.
RGNX
REGENXBIO Inc.
RGNX trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
RGNX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Strong |
RGNX's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
RGNX PE Valuation
RGNX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
RGNX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RGNX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over RGNX on earnings quality, reporting a profit while its opponent remains loss making.
RGNX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.21 | +$0.24 |
| Q2 2026 | -$3.79 | -$0.37 |
| Q1 2026 | -$5.60 | -$2.51 |
| Q4 2025 | -$3.76 | +$0.83 |
| Q3 2025 | -$3.45 | +$1.57 |
| Q2 2025 | -$3.42 | +$1.84 |
| Q1 2025 | -$3.09 | +$2.78 |
| Q4 2024 | -$4.59 | +$1.43 |
RGNX is still losing money, but far less than before: $3.21 per share over the past year, against $6.50 at its worst in late 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over RGNX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over RGNX on profitability, with a higher operating margin.
RGNX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.2M | -69% |
| Q2 2026 | $108M | +406% |
| Q1 2026 | $6.4M | -93% |
| Q4 2025 | $30.3M | +43% |
| Q3 2025 | $29.7M | +23% |
| Q2 2025 | $21.4M | -4.2% |
| Q1 2025 | $89M | +470% |
| Q4 2024 | $21.2M | -4.5% |
RGNX's revenue has slid since its 2021 peak: $9M last quarter, down 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -388% | -212 points |
| Q2 2026 | 27% | +323 points |
| Q1 2026 | -1304% | -1318 points |
| Q4 2025 | -190% | +52 points |
| Q3 2025 | -176% | +80 points |
| Q2 2025 | -296% | -45 points |
| Q1 2025 | 14% | +422 points |
| Q4 2024 | -242% | +46 points |
RGNX's operating margin was −388% last quarter, down 212 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over RGNX on cash generation, producing positive trailing cash flow while its opponent burns cash.
RGNX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +$94.9M |
| Q2 2026 | -$63M | -$13.3M |
| Q1 2026 | -$77.4M | -337% |
| Q4 2025 | -$52.8M | -$20.1M |
| Q3 2025 | -$56.5M | -$15.6M |
| Q2 2025 | -$49.7M | -$3.8M |
| Q1 2025 | $32.6M | +$88.6M |
| Q4 2024 | -$32.7M | +$9.2M |
RGNX has burned cash in almost every quarter: −$155M over the past year, against −$106M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over RGNX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
RGNX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +23% | +12.2M shares |
| 1 year | +26% | +13.6M shares |
| 3 years | +51% | +22.1M shares |
| 5 years | +76% | +28.2M shares |
RGNX has 65M diluted shares, up 26% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
RGNX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -1.0x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -1.3x | Net Cash |
| Q4 2021 | -2.0x | Net Cash |
RGNX has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
RGNX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.0 | Neutral |
| Stochastic | 20.6 | Neutral |
RGNX's weekly RSI is 47 (neutral) and its Stochastic is 21 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
RGNX PE vs Healthcare Sector
| Metric | RGNX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGNX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over RGNX on trend strength, trading above more of its moving averages.
RGNX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.42 | 8.2% above |
| 20 week MA | $9.16 | 12% below |
| 50 week MA | $9.59 | 16% below |
| 100 week MA | $9.22 | 13% below |
| 200 week MA | $12.9 | 38% below |
RGNX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 38% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over RGNX on returns for 2026, with the stronger performance.
RGNX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $48.7 | +20% |
| 2021 | $48.7 | $34.8 | -29% |
| 2022 | $34.8 | $22.3 | -36% |
| 2023 | $22.3 | $18.0 | -19% |
| 2024 | $18.0 | $7.41 | -59% |
| 2025 | $7.41 | $14.2 | +91% |
| 2026 YTD | $14.2 | $8.03 | -43% |
RGNX has finished lower in four of the last six years. It's down 43% so far in 2026.